<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">VANCOMYCIN HYDROCHLORIDE</span><br/>(van-koe-mye'sin)<br/><span class="topboxtradename">Vancocin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>125 mg, 250 mg capsules; 1 g, 10 g oral powder; 500 mg, 1 g injection</p>
<h1><a name="action">Actions</a></h1>
<p>Prepared from <i>Streptomyces orientalis,</i> with bactericidal and bacteriostatic actions. Acts by interfering with cell membrane synthesis in multiplying organisms.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Active against many gram-positive organisms, including group A beta-hemolytic <i>Streptococci, Staphylococci, Pneumococci, Enterococci, Clostridia,</i> and <i>Corynebacteria.</i> Gram-negative organisms, mycobacteria, and fungi are highly resistant.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Parenterally for potentially life-threatening infections in patients allergic, nonsensitive, or resistant to other less toxic
         antimicrobial drugs. Used orally only in <i>Clostridium difficile</i> colitis (not effective by oral route for treatment of systemic infections).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known hypersensitivity to vancomycin, allergy to corn or corn products, previous hearing loss, concurrent or sequential use
         of other ototoxic or nephrotoxic agents, IM administration.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Neonates; children; older adults; impaired kidney function, renal failure, renal impairment, concomitant administration of
         aminoglycosides; hearing impairment; colitis, inflammatory disorders of the intestine; pregnancy (category B), lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Systemic Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 500 mg q6h or 1 g q12h, infuse over 6090 min<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 40 mg/kg/d divided q6h, infuse over 6090 min<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV</span> 10 mg/kg/d divided q812h, infuse over 6090 min<br/><br/><span class="indicationtitle">
<i>Clostridium difficile</i> Colitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 125500 mg q6h<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 40 mg/kg/d divided q6h (max: 2 g/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Oral solution is prepared by adding to 10 g oral powder 115 mL of distilled water. The solution may be further diluted in
            10 g of water.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Reconstitute 500 mg vial or 1 g vial with 10 mL or 20 mL, respectively, of sterile water for injection to yield 50 mg/mL.
                  Further dilute each 1 g with at least 200 mL of D5W, NS, or RL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span> Give a single dose at a rate of 10 mg/min or over <small>NOT LESS</small> than 60 min. Avoid rapid infusion, which may cause sudden hypotension. Monitor IV site closely; necrosis and tissue sloughing
                  will result from extravasation.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Aminophylline,</b>
<span class="classification">barbiturates</span>, <b>cefotaxime,</b>
<b>chloramphenicol,</b>
<b>chlorothiazide,</b>
<b>dexamethasone,</b>
<b>heparin,</b>
<b>sodium bicarbonate,</b>
<b>warfarin.</b>
<span class="incompattype">Y-site:</span>
<b>Albumin,</b>
<b>aztreonam,</b>
<b>cefepime,</b>
<b>cefotaxime,</b>
<b>cefotetan,</b>
<b>cefoxitin,</b>
<b>ceftazidime,</b>
<b>ceftriaxone,</b>
<b>cefuroxime,</b>
<b>foscarnet,</b>
<b>heparin,</b>
<b>idarubicin,</b>
<b>nafcillin,</b>
<b>omeprazole,</b>
<b>piperacillin/tazobactam,</b>
<b>ticarcillin,</b>
<b>ticarcillin/clavulanate,</b>
<b>warfarin.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store oral and parenteral solutions in refrigerator for up to 14 d; after further dilution, parenteral solution is stable
            24 h at room temperature.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Special Senses:</span> Ototoxicity (auditory portion of eighth cranial nerve). <span class="typehead">Urogenital:</span>
<span class="speceff-life">Nephrotoxicity leading to uremia</span>. <span class="typehead">Body as a Whole:</span> Hypersensitivity reactions (chills, fever, skin rash, urticaria, <span class="speceff-life">shock-like state</span>), <span class="speceff-life">anaphylactoid reaction with vascular collapse</span>, superinfections, severe pain, thrombophlebitis at injection site, generalized tingling following rapid IV infusion. <span class="typehead">Hematologic:</span> Transient leukopenia, eosinophilia. <span class="typehead">GI:</span> Nausea, warmth. <span class="typehead">Other:</span> Injection reaction that includes <span class="speceff-common">hypotension accompanied by flushing and erythematous rash on face and upper body</span> ("red-neck syndrome") following rapid IV infusion. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Adds to toxicity of <span class="classification">ototoxic</span> and <span class="classification">nephrotoxic drugs</span> (<span class="classification">aminoglycosides</span>, <b>amphotericin B,</b>
<b>colistin,</b>
<b>capreomycin;</b>
<b>cidofovir;</b>
<b>cisplatin;</b>
<b>cyclosporine;</b>
<b>foscarnet;</b>
<b>ganciclovir;</b>
<b>IV pentamidine;</b>
<b>polymyxin B;</b>
<b>streptozocin;</b>
<b>tacrolimus</b>). <b>Cholestyramine,</b>
<b>colestipol</b> can decrease absorption of oral vancomycin; may increase risk of lactic acidosis with <b>metformin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Not absorbed from GI tract. <span class="typehead">Peak:</span> 30 min after end of infusion. <span class="typehead">Distribution:</span> Diffuses into pleural, ascitic, pericardial, and synovial fluids; small amount penetrates CSF if meninges are inflamed; crosses
      placenta. <span class="typehead">Elimination:</span> 8090% of IV dose excreted in urine within 24 h; PO dose excreted in feces. <span class="typehead">Half-Life:</span> 48 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP and heart rate continuously through period of drug administration.</li>
<li>Lab tests: Monitor urinalysis, kidney &amp; liver functions, and hematologic studies periodically.</li>
<li>Monitor serial tests of vancomycin blood levels (peak and trough) in patients with borderline kidney function, in infants
            and neonates, and in patients &gt;60 y.
         </li>
<li>Assess hearing. Drug may cause damage to auditory branch (not vestibular branch) of eighth cranial nerve, with consequent
            deafness, which may be permanent.
         </li>
<li>Be aware that serum levels of 6080 mcg/mL are associated with ototoxicity. Tinnitus and high-tone hearing loss may precede
            deafness, which may progress even after drug is withdrawn. Older adults and those on high doses are especially susceptible.
         </li>
<li>Monitor I&amp;O: Report changes in I&amp;O ratio and pattern. Oliguria or cloudy or pink urine may be a sign of nephrotoxicity (also
            manifested by transient elevations in BUN, albumin, and hyaline and granular casts in urine).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician promptly of ringing in ears.</li>
<li>Adhere to drug regimen (i.e., do not increase, decrease, or interrupt dosage. The full course of prescribed drug therapy must
            be completed).
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>